The CASP6 Knockout Huh-7 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Huh-7 hepatocellular carcinoma cell line, targeting the CASP6 gene. This loss-of-function model enables disruption of caspase-6 expression, providing a powerful tool for investigating the executioner phase of apoptosis and non-apoptotic roles of CASP6 in liver cancer biology.
Huh-7 is an established epithelial cell line originally isolated from a well-differentiated hepatocellular carcinoma of a 57-year-old Japanese male. Widely used in liver cancer research, Huh-7 cells retain many characteristics of transformed hepatocytes, including active signaling pathways relevant to hepatocarcinogenesis, drug metabolism, and apoptotic regulation. This provides a relevant cellular context for dissecting the contributions of CASP6 to hepatocellular carcinoma progression and therapeutic response.
CASP6 encodes caspase-6, a critical executioner caspase activated downstream of initiator caspases such as caspase-8 and caspase-9 upon intrinsic or extrinsic apoptotic stimuli. Following proteolytic activation, caspase-6 cleaves key substrates including lamin A, cytokeratin 18, PARP, and alpha-fodrin, facilitating the morphological and biochemical hallmarks of apoptosis. Activation is regulated by the apoptosome complex (cytochrome c/Apaf-1) and granzyme B, and is inhibited by XIAP and cIAP1/2. Caspase-6 closely interacts with caspase-3 and caspase-7 to coordinate proteolytic cascades. Representative pathway components include Bcl-2 family members (Bax, Bid) that control mitochondrial outer membrane permeabilization, linking upstream death signals to caspase activation.
In hepatocellular carcinoma, evasion of apoptosis is a hallmark of cancer progression and drug resistance. The CASP6 knockout Huh-7 polyclonal cells allow dissection of caspase-6-dependent and -independent cell death pathways, facilitating investigation of apoptosis resistance mechanisms and identification of vulnerabilities that can be targeted with pro-apoptotic agents. Furthermore, this model may reveal non-apoptotic functions of CASP6 relevant to liver inflammation and cancer cell survival signaling, expanding its utility beyond canonical apoptosis studies.
Typical applications include functional genomics, apoptosis research, and drug discovery, employing techniques such as caspase activity assays, Western blotting for cleaved substrates (e.g., lamin A, cytokeratin 18), TUNEL staining, Annexin V flow cytometry, and cell viability assays. This polyclonal knockout population supports mechanistic studies of caspase-6 in hepatocellular carcinoma and the development of novel therapeutics. For additional details or technical support, please contact Ascent Research.
